CAPOZIDE 25/25 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Capozide 25/25, and when can generic versions of Capozide 25/25 launch?
Capozide 25/25 is a drug marketed by Apothecon and is included in one NDA.
The generic ingredient in CAPOZIDE 25/25 is captopril; hydrochlorothiazide. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the captopril; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Capozide 25/25
A generic version of CAPOZIDE 25/25 was approved as captopril; hydrochlorothiazide by RISING on December 29th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CAPOZIDE 25/25?
- What are the global sales for CAPOZIDE 25/25?
- What is Average Wholesale Price for CAPOZIDE 25/25?
Summary for CAPOZIDE 25/25
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 13 |
| Clinical Trials: | 1 |
| Patent Applications: | 9 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CAPOZIDE 25/25 at DailyMed |
Recent Clinical Trials for CAPOZIDE 25/25
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 1 |
US Patents and Regulatory Information for CAPOZIDE 25/25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | CAPOZIDE 25/25 | captopril; hydrochlorothiazide | TABLET;ORAL | 018709-002 | Oct 12, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAPOZIDE 25/25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Apothecon | CAPOZIDE 25/25 | captopril; hydrochlorothiazide | TABLET;ORAL | 018709-002 | Oct 12, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Apothecon | CAPOZIDE 25/25 | captopril; hydrochlorothiazide | TABLET;ORAL | 018709-002 | Oct 12, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAPOZIDE 25/25
See the table below for patents covering CAPOZIDE 25/25 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1078385 | COMPOSES DE 6-OXA-1-AZATRICYCLODECAN-5-ONE (1,4-ETHANO-6-OXO-OCTAHYDRO-QUINOLINE AND 6-OXA-1-AZA TRICYCLODODECAN-5-ONE COMPOUNDS) | ⤷ Sign Up |
| Sweden | 7901316 | ⤷ Sign Up | |
| Argentina | 213184 | PROCEDIMIENTO PARA PREPARAR DERIVADOS DE 1,4-ETAN-6-OXO-PERHIDROQUINOLEINA Y SUS SALES | ⤷ Sign Up |
| Greece | 69811 | ⤷ Sign Up | |
| Italy | 7947986 | ⤷ Sign Up | |
| Australia | 1865476 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
